Rheumatological immune-related adverse events (irAEs) related to checkpoint inhibitor use in cancer patients appear to respond well to the usual rheumatology therapies, according to data presented at the ACR 2017 meeting in San Diego. A small retrospective study from the Royal Melbourne Hospital and Peter MacCallum Cancer Centre found 13 of 18 patients treated with ...
Cancer patients with rheum side effects respond well to usual therapy
By Mardi Chapman
7 Nov 2017